Back to mobile site

TD Cowen Reiterates Buy Rating on AnaptysBio (ANAB)

August 6, 2024 9:23 AM EDT Send to a Friend
TD Cowen analyst Joseph Thome reiterated a Buy rating on AnaptysBio (NASDAQ: ANAB).The analyst commented, "ANAB reported a net loss ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login